PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
May 05, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 13:31 ET
|
PMV Pharmaceuticals, Inc.
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral dosingPharmacodynamic biomarkers of p53 activation developed...
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
April 06, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 10, 2021 16:31 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
March 03, 2021 16:01 ET
|
PMV Pharmaceuticals, Inc.
Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationPC14586 granted Fast Track...
PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference
February 23, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
February 16, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
November 24, 2020 17:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
November 23, 2020 08:00 ET
|
PMV Pharmaceuticals, Inc.
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 13, 2020 08:00 ET
|
PMV Pharmaceuticals, Inc.
U.S. Food and Drug Administration (FDA) clearance of PMV Pharmaceutical’s investigational new drug application for its lead product candidate PC14586PMV Pharma lead product candidate PC14586 granted...